Clinical Trial Update: Hypertonic Modulation of Inflammation Following Injury

View source ↗

Summary

The clinical trial NCT00750997 investigating hypertonic modulation of inflammation after hemorrhagic shock and traumatic brain injury has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemorrhagic Shock
• Traumatic Brain Injury

Drugs mentioned

• Hypertonic saline (3% NaCl) (Hypertonic saline)

Snippet

Sponsor: University of Washington | Conditions: Hemorrhagic Shock, Traumatic Brain Injury | Status: TERMINATED